GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (HAM:MAH0) » Definitions » Net Margin %

Mereo BioPharma Group (HAM:MAH0) Net Margin % : -1,541.95% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Mereo BioPharma Group Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Mereo BioPharma Group's Net Income for the three months ended in Dec. 2023 was €-14.26 Mil. Mereo BioPharma Group's Revenue for the three months ended in Dec. 2023 was €0.93 Mil. Therefore, Mereo BioPharma Group's net margin for the quarter that ended in Dec. 2023 was -1,541.95%.

The historical rank and industry rank for Mereo BioPharma Group's Net Margin % or its related term are showing as below:

HAM:MAH0' s Net Margin % Range Over the Past 10 Years
Min: -294.66   Med: -129.88   Max: 34.9
Current: -294.66


HAM:MAH0's Net Margin % is ranked worse than
58% of 1019 companies
in the Biotechnology industry
Industry Median: -151.78 vs HAM:MAH0: -294.66

Mereo BioPharma Group Net Margin % Historical Data

The historical data trend for Mereo BioPharma Group's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Net Margin % Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial Premium Member Only - - 34.90 - -294.66

Mereo BioPharma Group Quarterly Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.44 - - -154.73 -1,541.95

Competitive Comparison of Mereo BioPharma Group's Net Margin %

For the Biotechnology subindustry, Mereo BioPharma Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mereo BioPharma Group's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Net Margin % distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Net Margin % falls into.



Mereo BioPharma Group Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Mereo BioPharma Group's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-27.02/9.17
=-294.66 %

Mereo BioPharma Group's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-14.263/0.925
=-1,541.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mereo BioPharma Group  (HAM:MAH0) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Mereo BioPharma Group Net Margin % Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (HAM:MAH0) Business Description

Comparable Companies
Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (HAM:MAH0) Headlines

No Headlines